Nature Reviews Immunology (2020) 10.1038/s41577-020-0331-4 Published online 06 May 2020
In the originally published article, the imprecise wording of a sentence implied that IL-6 blockade had been approved by the FDA for treatment of COVID-19. This has now been corrected in the HTML and PDF versions of the article to clarify that the FDA had, at the time of writing, only approved trials of IL-6 blockade in patients with COVID-19.
Contributor Information
Miriam Merad, Email: miriam.merad@mssm.edu.
Jerome C. Martin, Email: jerome.martin@univ-nantes.fr